For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240328:nRSb7457Ia&default-theme=true
RNS Number : 7457I Camellia PLC 28 March 2024
28 March 2024
Camellia Plc
(the "Company" or the "Group")
Update on BF&M disposal
As announced in June 2023, we agreed the sale of our 37% holding in BF&M
to Bermuda Life Insurance Company Limited, a subsidiary of Argus Group
Holdings Limited ("Argus") for a cash consideration of $100m (the "Sale"),
conditional on receipt of a number of regulatory and tax approvals.
Following the announcement of this proposed disposal, BF&M's board
implemented a shareholder rights agreement, the objective of which was to act
as a 'poison pill' in the event of any new shareholder seeking to register a
more than 15% shareholding without BF&M's consent. This shareholder rights
agreement has since been removed. However, BF&M thereafter separately
announced a partnership with Equilibria Capital Management Limited (Argus'
major shareholder) under which Equilibria will grant BF&M an exclusive
option to acquire a 13.7% stake in Argus. As part of this partnership,
BF&M has also committed to a significant investment in a dedicated
Equilibria investment fund which will include as its initial investment a
16.3% stake in Argus.
As previously communicated, these developments have impacted the anticipated
timetable for regulatory approvals for the Sale. While a number of the
required regulatory and tax approvals have been forthcoming, some key
approvals remain outstanding which we now expect in Q2 2024.
This announcement contains inside information for the purposes of the UK
Market Abuse Regulation.
Enquiries
Camellia Plc
01622 746655
Byron Coombs, CEO
Susan Walker, Chief Financial Officer
Panmure Gordon
020 7886 2500
Nominated Adviser and Broker
Emma Earl
Rupert Dearden
H/Advisors Maitland
PR
William Clutterbuck
07785 292617
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END MSCLVLFLZXLBBBK